USPTO serial 78506558
PAIONEER
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 5, 2010
- Examiner
- REGAN, JOHN B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PAIONEER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gary D. Krugman
Gary D. Krugman SUGHRUE MION, PLLC2100 PENNSYLVANIA AVENUE, NWWASHINGTON, DC 20037-3213UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for scientific or medical research use; diagnostic reagents for scientific or research use, biochemical reagents for scientific or medical research use; reagents for scientific or research use, none of the foregoing goods for use in the agricultural industry, including biopharming | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood clotting test kits comprised of medical diagnostic reagents; medical and clinical diagnostic reagents for clinical or medical laboratory use, none of the foregoing goods for use in the agricultural industry, including biopharming | SECTION 8 - CANCELLED | — |
| 035 | Computerized database management, namely, editing, evaluating and processing data for third parties | SECTION 8 - CANCELLED | — |
| 041 | Educational services, namely, providing informational events in the nature of seminars and workshops in the fields of pharmacology, medical procedures, product research and development of medical devices and pharmaceutical preparations, none of the foregoing services offered to the agricultural industry, including biopharming | SECTION 8 - CANCELLED | — |
| 042 | Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; licensing of intellectual property; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, providing pharmaceutical advice to others regarding governmental regulatory laws and practices, performing pre-clinical studies, quality control; preparation of expert opinions in the field biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, product research and development of medical devices and pharmaceutical preparations, and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; bio-chemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment. scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment, none of the foregoing services offered to the agricultural industry, including biopharming | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Paion GmbH
- Other trademarks owned by PAION DEUTSCHLAND GMBH
- Other trademarks owned by PAION DEUTSCHLAND GMBH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named PAIONEER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 12, 2016 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 5, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 4, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 1, 2009 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Dec 1, 2009 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Dec 1, 2009 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jan 15, 2009 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Nov 7, 2008 | CRTP | REG. CANCELLED - RESTORED TO PENDENCY | — |
| Oct 31, 2008 | APET | ASSIGNED TO PETITION STAFF | — |
| Oct 10, 2008 | RCII | REQUEST TO CANCEL INADVERTENTLY ISSUED REGISTRATION RECEIVED | — |
| Sep 30, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 14, 2008 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Aug 14, 2008 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jul 15, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 25, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 6, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 3, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 3, 2008 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 3, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 2, 2008 | ALIE | ASSIGNED TO LIE | — |
| Jun 2, 2008 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 2, 2008 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 2, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 2, 2008 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 2, 2008 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Jun 2, 2008 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 18, 2008 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 18, 2008 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 18, 2008 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 16, 2008 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Apr 16, 2008 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Apr 16, 2008 | APET | ASSIGNED TO PETITION STAFF | — |
| Apr 11, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 11, 2008 | PDCB | PETITION TO DIRECTOR - CHANGE BASIS - RECEIVED | — |
| Apr 11, 2008 | PAPER RECEIVED | — | |
| Oct 22, 2007 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 22, 2007 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 22, 2007 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 27, 2007 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 18, 2007 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 18, 2007 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 11, 2006 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 11, 2006 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 11, 2006 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 25, 2006 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 4, 2006 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Oct 25, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 25, 2005 | PAPER RECEIVED | — | |
| Oct 20, 2005 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Oct 4, 2005 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 14, 2005 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 12, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 10, 2005 | ALIE | ASSIGNED TO LIE | — |
| Aug 2, 2005 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 2, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jul 27, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 27, 2005 | PAPER RECEIVED | — | |
| Jun 2, 2005 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 2, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2004 | NWAP | NEW APPLICATION ENTERED | — |